959 results on '"Vassilakopoulos, Theodoros P."'
Search Results
2. Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version
3. How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma?
4. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
5. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries
6. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
7. The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications
8. Cerebral venous sinus thrombosis in the setting of COVID-19 vaccination: a systematic review and meta-analysis
9. A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece
10. Thrombocytosis
11. Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature
12. H10: Long-Term Results Could Be Misleading Without an Updated Reading Key for Positron Emission Tomography
13. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
14. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
15. Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
16. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
17. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
18. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
19. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine
20. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
21. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
22. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
23. How to ventilate obstructive and asthmatic patients
24. What’s new about pulmonary hyperinflation in mechanically ventilated critical patients
25. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
26. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
27. The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications
28. Malignant Lymphomas Introduction
29. Prognostic Impact of Serum β 2 -Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients.
30. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
31. Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma
32. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
33. A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity
34. Prolonged 3-year spontaneous remission of diffuse large B-cell lymphoma upon withdrawal of infliximab and late relapse in a patient with psoriasis: a case report and review of the literature
35. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
36. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
37. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome
38. The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece
39. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
40. Aggressive B-Cell Lymphomas
41. PET/CT in Hodgkin Lymphoma
42. An Overview of the Clinical Evaluation of Lymphomas According to the WHO 2008 Classification
43. Treatment of splenic marginal zone lymphoma
44. Treatment intensification might not improve survival in high‐grade B‐cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
45. Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization
46. Supplementary Table S1 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
47. Supplementary Methods from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
48. Data from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
49. Supplementary Figure S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
50. Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.